MedPage Today (5/6, Susman) reported that, according to a study presented at a vision research meeting, "the ability to read a newspaper or even prepare a meal -- functions that require near-vision abilities -- appear to improve when patients with the 'wet' form of age-related macular degeneration (AMD) undergo treatment with ranibizumab (Lucentis)." For the study, researchers at Sweden's Linkoping University recruited 30 patients. After using ranibizumab, the patients "achieved a 50 percent improvement in their ability to read newspapers and a 30 percent improvement in all types of near-vision activities." The authors concluded that "ranibizumab offers a most valuable treatment for wet" AMD. Emily Chew, MD, of the National Eye Institute, who was not involved with the study, "noted that while the ability to perform near activities improves quality of life, treatment with drugs such as ranibizumab also control eye disease and can prevent progression of age-related macular degeneration." (courtesyAOA)
No comments:
Post a Comment